292644-27-0

Basic information

• Product Name: TARTARIC DIHYDRAZIDE
• Synonyms: TARTARIC DIHYDRAZIDE
• CAS NO: 292644-27-0
• Molecular Formula: C4H10N4O4
• Molecular Weight: 178.15
• Mol File: 292644-27-0.mol

Chemical Properties

• Melting Point: 181-184 °C
• Boiling Point: 724.9±60.0 °C(Predicted)
• Appearance: /
• Density: 1.626±0.06 g/cm3(Predicted)
• PKA: 11.46±0.50(Predicted)
• CAS DataBase Reference: TARTARIC DIHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: TARTARIC DIHYDRAZIDE(292644-27-0)
• EPA Substance Registry System: TARTARIC DIHYDRAZIDE(292644-27-0)

Safety Data

• Hazardous Substances Data: 292644-27-0(Hazardous Substances Data)

Upstream product

• 405897-14-5 dimethyl tartrate 
• 87-69-4 tartaric acid 
• 408332-88-7 Diethyl tartrate 

Downstream Products

• 72743-53-4 C₂₀H₂₄N₆O₄S₂ 
• 72743-54-5 C₂₀H₂₄N₆O₄S₂ 

Relevant articles and documents

Metallopharmaceutical complexes based on vanadium as potential anti-hyperglycemic agents

Interaction between vanadium pentoxide and bioactive Schiff bases led to the formation of vanadium (III/IV) complexes. Ten complexes have been characterized using mass, IR, UVVIS and ESR spectra, magnetic moments and conductance measurements as well as elemental and thermal analyses. Magnetic moments and ESR measurements confirmed vanadium complexes have (III/IV) oxidation state. Conductivity measurements indicate that complexes are not electrolytes. A representative set of vanadium (III/IV) complexes in varying coordination environments have been tested as anti-hyperglycemic agents against type 2 diabetes mellitus in concentration doses (30 and 100 ?M/Kg) using female albino rats. The pharmacological data showed that, complexes 1 and 8 produced significant decrease in blood glucose level. Furthermore, these two complexes showed an improvement in liver and kidney function after daily administration for two weeks.

Synthesis and biological evaluation of bis-N2,N2′-(4-hydroxycoumarin-3-yl)ethylidene]-2,3-dihydroxysuccinodihydrazides

A series of N2,N2′-bis[4-hydroxycoumarin-3-yl)ethylidene]-2,3-dihydroxysuccino-hydrazides, containing 4-hydroxycoumarin, hydrazine and tartaric acid moieties, have been prepared and examined for possible biological activity. Several of these compounds exhibit promising HIV-1 integrase inhibition (IC50 = 3.5 μM), and anti-T. brucei (32% viability) and anti-mycobacterial (Visual MIC90 = 15.63 μM) activity.

Continuous hydrazide preparation method

The invention relates to a continuous hydrazide preparation method. The preparation method includes: in a micro-channel reactor or a pipeline reactor, subjecting esters, anhydrides or acyl chloride tocontinuous reaction with hydrazine or solution of hydrazine under a solvent-free condition or in a solvent to prepare a hydrazide compound. The preparation method is simple, short in technical process, less in waste gas, wastewater and industrial residues, beneficial to environmental production and suitable for industrial production. The adopted reactor is short in reaction time, high in safety and capable of realizing continuous production. The adopted reactor is high in workshop space utilization rate, and large-scale production can be realized. By adoption of the preparation method, solvent recycling can be realized, and production cost is reduced; in addition, high raw material conversion rate, high quality stability and high purity are realized.